Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.
Status:
Terminated
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
Renal cell carcinoma represents today 3% of the solid tumors of the adult. Their bad
prognosis is due to the frequency of metastasis and the resistance to chemotherapy.
Immunotherapy (interferon-α, interleukin-2) has shown some good results but an important
toxicity. In our study, we evaluate the response to a new therapeutic strategy which combines
an injection of patient's own activated lymphocytes to a classic immunotherapy with
interferon-α and interleukin-2.